環保專案成果報告查詢系統

專案計畫編號
經費年度	113
計畫經費	10,085 千元
預算科目	水污染防治-永續水質推動計畫2.0－河川環境品質提升計畫
專案開始日期	2024/03/04
專案結束日期	2024/11/30
專案主持人	許國恩
主辦單位	環境部水質保護司
承辦人	郭權展
執行單位	財團法人中興工程顧問社
專案分類	水質保護
中文關鍵字	放流水標準、藥物與個人保健用品、持久性有機污染物
英文關鍵字	Effluent standard, Pharmaceuticals and Personal Care Products, Persistent Organic Pollutants
協同主持人
共同主持人
計畫聯絡人	林宜璇
計畫聯絡電話	(02) 87919198 #658
計畫聯絡信箱	yhlin@sinotech.org.tw

中文摘要	計畫已歸納國內外持久性有機污染物管理管制動態及國內事業製程運作情形，並調查廢污水全氟化合物、得克隆及UV-328濃度。23個樣品18項全氟化物檢出濃度介於0.00118~2.25 μg/L；22點次水樣檢測結果顯示均無檢出順式得克隆及反式得克隆；20點次水樣UV-328檢出濃度介於0.00754~16.9 μg/L。另外，計畫調查國內醫院、公共污水下水道系統廢污水及環境水體之9項藥物濃度，醫院原廢水濃度最高之藥物為頭孢他啶 (2.34~6,480 μg/L) ，放流水濃度最高之藥物亦為頭孢他啶 (0.244~2,390 μg/L)。公共污水處理廠原污水檢出濃度最高之藥物為二甲雙胍 (57.1、101 μg/L)，放流水檢出濃度最高之藥物為頭孢他啶 (9.23、11.6 μg/L)。環境水體僅二甲雙胍檢出濃度高於1 μg/L。為確保河川水體品質，本計畫針對氨氮、硼、戴奧辛及發電廠燃煤總汞等進行盤點與調查，掌握事業廢污水之排放風險。調查結果顯示2家電鍍業放流水硼濃度超過管制限值。此外，本計畫已協助研擬放流水標準修正草案 (有關磷管制議題等)，以及水污染防治措施及檢測申報管理辦法修正草案 (有關全氟化合物、藥物檢測申報議題)。
中文關鍵字	放流水標準、藥物與個人保健用品、持久性有機污染物

中文摘要

計畫已歸納國內外持久性有機污染物管理管制動態及國內事業製程運作情形，並調查廢污水全氟化合物、得克隆及UV-328濃度。23個樣品18項全氟化物檢出濃度介於0.00118~2.25 μg/L；22點次水樣檢測結果顯示均無檢出順式得克隆及反式得克隆；20點次水樣UV-328檢出濃度介於0.00754~16.9 μg/L。另外，計畫調查國內醫院、公共污水下水道系統廢污水及環境水體之9項藥物濃度，醫院原廢水濃度最高之藥物為頭孢他啶 (2.34~6,480 μg/L) ，放流水濃度最高之藥物亦為頭孢他啶 (0.244~2,390 μg/L)。公共污水處理廠原污水檢出濃度最高之藥物為二甲雙胍 (57.1、101 μg/L)，放流水檢出濃度最高之藥物為頭孢他啶 (9.23、11.6 μg/L)。環境水體僅二甲雙胍檢出濃度高於1 μg/L。為確保河川水體品質，本計畫針對氨氮、硼、戴奧辛及發電廠燃煤總汞等進行盤點與調查，掌握事業廢污水之排放風險。調查結果顯示2家電鍍業放流水硼濃度超過管制限值。此外，本計畫已協助研擬放流水標準修正草案 (有關磷管制議題等)，以及水污染防治措施及檢測申報管理辦法修正草案 (有關全氟化合物、藥物檢測申報議題)。

中文關鍵字

放流水標準、藥物與個人保健用品、持久性有機污染物

類型	檔名	檔案大小	說明	最新版公開日期
期末報告	113年事業廢水特性分析及管理評估計畫成果報告.pdf	23MB		2025/1/9 上午 12:00:00

摘要	The project has summarized both domestic and foreign persistent organic pollutants (POPs) management and the industrial POPs usage in Taiwan. It also investigated the concentrations of perfluorinated compounds (PFCs), Dechlorane Plus (DP), and UV-328 in wastewater. The analysis of 23 samples revealed that the concentrations of 18 PFCs ranged from 0.00118 to 2.25 μg/L. No syn-DP or anti-DP was detected in 22 water samples, while the concentration of UV-328 was detected in 20 samples, ranging from 0.00754 to 16.9 μg/L. In addition, the project investigated the concentrations of nine pharmaceutical compounds in wastewater from domestic hospitals, public sewage treatment plants, and environmental water bodies. The highest concentration of pharmaceuticals in hospital raw wastewater was observed for ceftazidime (2.34–6,480 μg/L), and the highest concentration in hospital effluent was also for ceftazidime (0.244–2,390 μg/L). In public sewage treatment plants, the highest detected concentration in raw wastewater was for metformin (57.1 and 101 μg/L), and in effluent, the highest concentration was again for ceftazidime (9.23 and 11.6 μg/L). Only metformin was detected in environmental water bodies at concentrations exceeding 1 μg/L. To ensure river water quality, the project also conducted surveys on ammonia nitrogen, boron, dioxins, and total mercury of coal in coal-fired power plants, assessing the pollution risk of wastewater discharge. The findings indicated that two electroplating industries had effluent boron concentrations exceeding the effluent standard. Furthermore, the project assisted in drafting amendments to Effluent Standards (addressing issues such as phosphorus control) and proposed revisions to Water Pollution Control Measures and Test Reporting Management Regulations (focusing on the test reporting of PFCs and pharmaceuticals).
英文關鍵字	Effluent standard, Pharmaceuticals and Personal Care Products, Persistent Organic Pollutants

摘要

The project has summarized both domestic and foreign persistent organic pollutants (POPs) management and the industrial POPs usage in Taiwan. It also investigated the concentrations of perfluorinated compounds (PFCs), Dechlorane Plus (DP), and UV-328 in wastewater. The analysis of 23 samples revealed that the concentrations of 18 PFCs ranged from 0.00118 to 2.25 μg/L. No syn-DP or anti-DP was detected in 22 water samples, while the concentration of UV-328 was detected in 20 samples, ranging from 0.00754 to 16.9 μg/L. In addition, the project investigated the concentrations of nine pharmaceutical compounds in wastewater from domestic hospitals, public sewage treatment plants, and environmental water bodies. The highest concentration of pharmaceuticals in hospital raw wastewater was observed for ceftazidime (2.34–6,480 μg/L), and the highest concentration in hospital effluent was also for ceftazidime (0.244–2,390 μg/L). In public sewage treatment plants, the highest detected concentration in raw wastewater was for metformin (57.1 and 101 μg/L), and in effluent, the highest concentration was again for ceftazidime (9.23 and 11.6 μg/L). Only metformin was detected in environmental water bodies at concentrations exceeding 1 μg/L. To ensure river water quality, the project also conducted surveys on ammonia nitrogen, boron, dioxins, and total mercury of coal in coal-fired power plants, assessing the pollution risk of wastewater discharge. The findings indicated that two electroplating industries had effluent boron concentrations exceeding the effluent standard. Furthermore, the project assisted in drafting amendments to Effluent Standards (addressing issues such as phosphorus control) and proposed revisions to Water Pollution Control Measures and Test Reporting Management Regulations (focusing on the test reporting of PFCs and pharmaceuticals).

英文關鍵字

Effluent standard, Pharmaceuticals and Personal Care Products, Persistent Organic Pollutants